About Mitochondrial dicarboxylate carrier
Mitochondrial dicarboxylate carrier (SLC25A10) is a protein
from Homo sapiens identified by UniProt accession
Q9UBX3, 287 residues long.
MolForge cross-references it against 0 known binders and
61 disease associations.
Target properties
| Protein name | Mitochondrial dicarboxylate carrier |
|---|
| UniProt accession | Q9UBX3 |
|---|
| Gene | SLC25A10 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 287 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (61)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.50
- mitochondrial DNA depletion syndrome 19 · score 0.44
- mitochondrial complex I deficiency · score 0.27
- cutaneous melanoma · score 0.13
- squamous cell lung carcinoma · score 0.11
- hair color · score 0.10
- endometrial cancer · score 0.09
- total blood protein measurement · score 0.06
- creatinine measurement · score 0.04
- Familial exudative vitreoretinopathy · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9UBX3-F1 | alphafold | PREDICTED | 77.63 | — |
Amino-acid sequence (287 residues)
MAAEARVSRW YFGGLASCGA ACCTHPLDLL KVHLQTQQEV KLRMTGMALR VVRTDGILAL YSGLSASLCR QMTYSLTRFA IYETVRDRVA KGSQGPLPFH EKVLLGSVSG LAGGFVGTPA DLVNVRMQND VKLPQGQRRN YAHALDGLYR VAREEGLRRL FSGATMASSR GALVTVGQLS CYDQAKQLVL STGYLSDNIF THFVASFIAG GCATFLCQPL DVLKTRLMNS KGEYQGVFHC AVETAKLGPL AFYKGLVPAG IRLIPHTVLT FVFLEQLRKN FGIKVPS
Explore Mitochondrial dicarboxylate carrier with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets